Nonpharmacological Treatment Strategies for the Management of Canine Chronic Inflammatory Enteropathy-A Narrative Review

Chronic inflammatory enteropathy (CIE) refers to a heterogeneous group of idiopathic diseases of the dog characterised by persistent gastrointestinal (GI) clinical signs. If conventional dietary treatment alone would be unsuccessful, management of CIE is traditionally attained by the use of pharmace...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary sciences 2022-01, Vol.9 (2), p.37
Main Authors: Isidori, Marco, Corbee, Ronald Jan, Trabalza-Marinucci, Massimo
Format: Article
Language:English
Subjects:
Antibiotics
Antigens
Bioactive compounds
Biopsy
canine chronic inflammatory enteropathy
Chemokines
clinical nutrition
Cytokines
Disease
Dogs
Drug development
Immunology
Immunomodulation
Immunosuppressive agents
Inflammation
Inflammatory bowel disease
Intestinal microflora
Intestine
Mesenchyme
Microbiota
Microorganisms
Mucosa
Permeability
phytochemical
postbiotic
prebiotic
probiotic
Quality of life
Review
Stem cell transplantation
Stem cells
Therapeutic targets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic inflammatory enteropathy (CIE) refers to a heterogeneous group of idiopathic diseases of the dog characterised by persistent gastrointestinal (GI) clinical signs. If conventional dietary treatment alone would be unsuccessful, management of CIE is traditionally attained by the use of pharmaceuticals, such as antibiotics and immunosuppressive drugs. While being rather effective, however, these drugs are endowed with side effects, which may impact negatively on the animal's quality of life. Therefore, novel, safe and effective therapies for CIE are highly sought after. As gut microbiota imbalances are often associated with GI disorders, a compelling rationale exists for the use of nonpharmacological methods of microbial manipulation in CIE, such as faecal microbiota transplantation and administration of pre-, pro-, syn- and postbiotics. In addition to providing direct health benefits to the host via a gentle modulation of the intestinal microbiota composition and function, these treatments may also possess immunomodulatory and epithelial barrier-enhancing actions. Likewise, intestinal barrier integrity, along with mucosal inflammation, are deemed to be two chief therapeutic targets of mesenchymal stem cells and selected vegetable-derived bioactive compounds. Although pioneering studies have revealed encouraging findings regarding the use of novel treatment agents in CIE, a larger body of research is needed to address fully their mode of action, efficacy and safety.
ISSN:2306-7381
2306-7381
DOI:10.3390/vetsci9020037